Form D · Pharmaceuticals
General Oncology, Inc.
Newton, MA · CIK 0001658021
Offering snapshot reported Apr 23, 2026 · SEC filing
- Reported sold
- $4.81M Offering amount: $4.81M
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 23, 2026 | Initial | $4,805,299 | No comparison | 37 | SEC filing |
| Jul 2, 2025 | Amendment | $10,879,308 | $3,675,587vs Jul 2, 2024 | 43 | SEC filing |
| Jul 2, 2024 | Amendment | $7,203,721 | $1,175,000vs Dec 21, 2023 | 35 | SEC filing |
| Dec 21, 2023 | Amendment | $6,028,721 | $2,825,000vs Dec 22, 2022 | 34 | SEC filing |
| Dec 22, 2022 | Amendment | $3,203,721 | $0vs Nov 10, 2022 | 31 | SEC filing |
| Nov 10, 2022 | Amendment | $3,203,721 | $898,721vs Nov 10, 2021 | 31 | SEC filing |
| Nov 10, 2021 | Amendment | $2,305,000 | $876,250vs Dec 23, 2020 | 29 | SEC filing |
| Dec 23, 2020 | Amendment | $1,428,750 | $698,750vs Jul 14, 2020 | 19 | SEC filing |
| Jul 14, 2020 | Amendment | $730,000 | $285,000vs Jul 9, 2019 | 12 | SEC filing |
| Jul 9, 2019 | Initial | $445,000 | No comparison | 8 | SEC filing |
| Sep 5, 2017 | Amendment | $34,803,641 | $3,463,000vs Nov 16, 2015 | 140 | SEC filing |
| Nov 16, 2015 | Initial | $31,340,641 | No comparison | 129 | SEC filing |
Offering details
- Securities
- Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-581608
Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.
Source: Form D, filed Apr 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abid Ansari | Executive |
| Henry Esber | Director |
| Jeffrey Aaron Glazier | Director, Executive |
| Arnold Glazier | Director, Executive |
| Gregg Goldstein | Director, Executive |
| Michael J. Petit | Director |
| Barry Seeman | Director |
| Michael D. Sigman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
57 Chapel Street, Third Floor
Newton, MA, 02458
Phone: 617-468-4646
Newton, MA, 02458
Phone: 617-468-4646